이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Perspective Therapeutics 미래 성장

Future 기준 확인 2/6

Perspective Therapeutics은 연간 수입과 매출이 각각 13.7%와 79.6% 증가할 것으로 예상되고 EPS는 연간 20.1%만큼 증가할 것으로 예상됩니다.

주요 정보

1.2%

수익 성장률

11.6%

EPS 성장률

Biotechs 수익 성장	34.8%
매출 성장률	82.0%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	30 Sep 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

DB:AAJ0 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	0	-83	-53	-74	6
12/31/2025	0	-71	-84	-71	9
12/31/2024	1	-54	-65	-45	8
6/30/2024	1	-52	-25	-14	N/A
3/31/2024	2	-50	-23	-13	N/A
12/31/2023	1	-37	-38	-37	N/A
9/30/2023	1	-20	-33	-32	N/A
6/30/2023	1	-13	-25	-24	N/A
3/31/2023	3	-6	-19	-19	N/A
12/31/2022	5	-8	-11	-10	N/A
9/30/2022	10	-9	-8	-7	N/A
6/30/2022	N/A	-6	-8	-8	N/A
3/31/2022	11	-6	-6	-6	N/A
12/31/2021	11	-6	-5	-5	N/A
9/30/2021	10	-5	-5	-5	N/A
6/30/2021	10	-3	-3	-3	N/A
3/31/2021	10	-4	-3	-3	N/A
12/31/2020	10	-3	-3	-3	N/A
9/30/2020	10	-3	-4	-3	N/A
6/30/2020	10	-3	-4	-4	N/A
3/31/2020	9	-3	-4	-4	N/A
12/31/2019	8	-4	-5	-4	N/A
9/30/2019	8	-4	-5	-4	N/A
6/30/2019	7	-5	-5	-5	N/A
3/31/2019	7	-6	-6	-6	N/A
12/31/2018	7	-7	-6	-5	N/A
9/30/2018	6	-7	-6	-6	N/A
6/30/2018	6	-7	-6	-6	N/A
3/31/2018	6	-6	N/A	-5	N/A
12/31/2017	5	-6	N/A	-6	N/A
9/30/2017	5	-6	N/A	-6	N/A
6/30/2017	5	-6	N/A	-6	N/A
3/31/2017	5	-6	N/A	-6	N/A
12/31/2016	4	-5	N/A	-5	N/A
9/30/2016	5	-5	N/A	-4	N/A
6/30/2016	5	-5	N/A	-4	N/A
3/31/2016	5	-5	N/A	-3	N/A
12/31/2015	5	-4	N/A	-4	N/A
9/30/2015	5	-4	N/A	-3	N/A
6/30/2015	5	-4	N/A	-4	N/A
3/31/2015	4	-4	N/A	-4	N/A
12/31/2014	4	-5	N/A	-3	N/A
9/30/2014	4	-5	N/A	-3	N/A
6/30/2014	4	-7	N/A	-3	N/A
3/31/2014	4	-6	N/A	-3	N/A
12/31/2013	5	-5	N/A	-3	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AAJ0 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: AAJ0 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: AAJ0 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: AAJ0 의 수익(연간 79.6% ) German 시장( 5.2% 보다 빠르게 성장할 것으로 예상됩니다. 5.2% 연간).

고성장 수익: AAJ0 의 수익(연간 79.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AAJ0 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Perspective Therapeutics 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

High number of new and inexperienced directors

Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings released: US$0.024 loss per share (vs US$0.002 loss in 1Q 2023)

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Revenue size

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought €128k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.029 loss in 3Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Second quarter 2023 earnings released: US$0.04 loss per share (vs US$0.015 loss in 2Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.011 loss in 2Q 2022)

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings released: US$0.029 loss per share (vs US$0.016 loss in 1Q 2022)

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings released: US$0.051 loss per share (vs US$0.033 loss in FY 2021)

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.006 loss in 3Q 2021)

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견